5355W-12 LIBERATE Thoracic - Emphysema

Lung Function Improvement after Bronchoscopic Lung Volume Reduction with Pulmonx Endobronchial Valves used in Treatment of Emphysema (LIBERATE STUDY)

Type of Study
Swedish Thoracic Surgery / First Hill
Short Description

Purpose:  This study is designed to investigate the safety and effectiveness of the Pulmonx Endobronchial Valve (EBV) for treating emphysema symptoms as compared to a standard medical therapy program alone.

Open to Enrollment
Principal Investigator
Jed Gorden, M.D.
Eligibility Notes
Inclusion Criteria:
  • Clinical and radiological evidence of emphysema
  • Currently non-smoking
  • Stable on current medication regimen
  • Forced expiratory volume in one second (FEV1) between 15% and 45% of predicted value

Exclusion Criteria:

  • Had two or more hospitalizations over the last year for a COPD exacerbation
  • Had two or more hospitalizations over the last year for pneumonia
  • Had a prior lung transplant, lung volume reduction surgery, bullectomy or lobectomy
  • Had a heart attack or congestive heart failure within the last 6 months
  • Have heart arrhythmia
  • Is alpha-1 antitrypsin deficient
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
Contact Name
Tina Brennan
(206) 386-2450